MA52365A - Composés et leurs utilisations - Google Patents
Composés et leurs utilisationsInfo
- Publication number
- MA52365A MA52365A MA052365A MA52365A MA52365A MA 52365 A MA52365 A MA 52365A MA 052365 A MA052365 A MA 052365A MA 52365 A MA52365 A MA 52365A MA 52365 A MA52365 A MA 52365A
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862662673P | 2018-04-25 | 2018-04-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52365A true MA52365A (fr) | 2021-03-03 |
Family
ID=68290767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052365A MA52365A (fr) | 2018-04-25 | 2019-04-24 | Composés et leurs utilisations |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10919885B2 (fr) |
| EP (1) | EP3784234A1 (fr) |
| JP (1) | JP2021522253A (fr) |
| CN (1) | CN112566636A (fr) |
| MA (1) | MA52365A (fr) |
| WO (1) | WO2019209962A1 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019533022A (ja) | 2016-10-24 | 2019-11-14 | ユマニティ セラピューティクス，インコーポレーテッド | 化合物及びその使用 |
| CA3049010A1 (fr) | 2017-01-06 | 2018-07-12 | Yumanity Therapeutics, Inc. | Methodes de traitement de troubles neurologiques |
| CA3083000A1 (fr) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Composes et utilisations de ces composes |
| CA3094527A1 (fr) | 2018-03-23 | 2019-09-26 | Yumanity Therapeutics, Inc. | Composes et leurs utilisations |
| EP3774782A2 (fr) | 2018-04-06 | 2021-02-17 | Black Belt TX Ltd | Inhibiteurs d'atf6 et leurs utilisations |
| US12098146B2 (en) | 2019-01-24 | 2024-09-24 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| CN119751439A (zh) * | 2019-10-09 | 2025-04-04 | 阿尔托斯实验室公司 | Atf6调节剂及其用途 |
| CN119823112A (zh) * | 2019-10-09 | 2025-04-15 | 阿尔托斯实验室公司 | Atf6调节剂及其用途 |
| US20220406429A1 (en) * | 2019-11-04 | 2022-12-22 | The Regents Of The University Of California | Artificial Intelligence Enabled Control of Hemodynamics in Surgery Patients |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| CR20230115A (es) | 2020-09-03 | 2023-04-11 | Hoffmann La Roche | Compuestos heterocíclicos |
| KR20240000574A (ko) * | 2021-04-23 | 2024-01-02 | 에프. 호프만-라 로슈 아게 | 헤테로시클릭 화합물 |
| EP4341245A1 (fr) * | 2021-05-21 | 2024-03-27 | Basf Se | Utilisation de composés d'éthynylpyridine en tant qu'inhibiteurs de nitrification |
| EP4514782B1 (fr) | 2022-05-19 | 2025-09-10 | Astrazeneca AB | Composés amido hétéroaromatiques utiles dans le traitement de maladies hépatiques |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004014902A2 (fr) | 2002-08-09 | 2004-02-19 | Astrazeneca Ab | Nouveaux composes |
| BRPI0418149A (pt) | 2003-12-24 | 2007-04-17 | Prosidion Ltd | derivados heterocìclicos como agonistas do receptor de gprc |
| ES2325836T3 (es) | 2004-07-26 | 2009-09-21 | Merck Serono Sa | Derivados de la n.hidroxiamida y uso de los mismos. |
| JP4958786B2 (ja) | 2004-09-20 | 2012-06-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 複素環誘導体および治療薬としてのそれらの使用 |
| MX2007003319A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como agentes terapeuticos. |
| CA2610196A1 (fr) | 2005-06-09 | 2006-12-14 | Merck Frosst Canada Ltd. | Derives d'azacyclohexane comme inhibiteurs de la stearoyl-coenzyme a delta-9 desaturase |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| CA2654792A1 (fr) | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Derives d'azetidine comme inhibiteurs de la stearoyl-coenzyme a delta-9 desaturase |
| EP2121671A1 (fr) * | 2006-12-20 | 2009-11-25 | Novartis AG | Hétérocycles à 5 chaînons substitués en position 2 comme inhibiteurs de scd |
| CA2697551C (fr) | 2007-09-20 | 2013-03-12 | Irm Llc | Composes et compositions en tant que modulateurs de l'activite de gpr119 |
| GB0722077D0 (en) * | 2007-11-09 | 2007-12-19 | Smithkline Beecham Corp | Compounds |
| US8642660B2 (en) * | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| KR20100134680A (ko) | 2008-03-20 | 2010-12-23 | 포레스트 래보러토리즈 홀딩스 리미티드 | 스테아로일-ｃｏａ 불포화효소의 저해물질로서 신규한 피페리딘 유도체 |
| TWI434842B (zh) | 2008-07-14 | 2014-04-21 | Astellas Pharma Inc | Azole compounds |
| WO2010022055A2 (fr) | 2008-08-20 | 2010-02-25 | Amgen Inc. | Inhibiteurs de canaux sodiques sensibles au potentiel |
| WO2010039186A2 (fr) | 2008-09-23 | 2010-04-08 | Renovis, Inc. | Composés utiles en tant que modulateurs de la faah et leurs utilisations |
| US20120010186A1 (en) | 2009-03-23 | 2012-01-12 | Merck Frosst Canada Ltd. | Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| BR112012015248B1 (pt) | 2009-12-23 | 2022-01-04 | Jasco Pharmaceuticals, LLC | Composto |
| BR112014003963A2 (pt) | 2011-09-01 | 2017-03-21 | Irm Llc | compostos e composições como inibidores de quinase c-kit |
| MX2014004426A (es) | 2011-10-15 | 2014-07-09 | Genentech Inc | Metodos de uso de antagonistas de scd1. |
| US20130225529A1 (en) | 2012-02-27 | 2013-08-29 | Basil Rigas | Phospho-ester derivatives and uses thereof |
| AU2013328301A1 (en) | 2012-10-10 | 2015-05-28 | Actelion Pharmaceuticals Ltd | Orexin receptor antagonists which are [ortho bi (hetero-)aryl]-[2-(meta bi (hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives |
| EP3257510B1 (fr) * | 2015-02-09 | 2021-10-20 | National University Corporation Okayama University | Inhibiteur de la lactate déshydrogénase et médicament antiépileptique le contenant |
| JP2019533022A (ja) | 2016-10-24 | 2019-11-14 | ユマニティ セラピューティクス，インコーポレーテッド | 化合物及びその使用 |
-
2019
- 2019-04-24 WO PCT/US2019/028928 patent/WO2019209962A1/fr not_active Ceased
- 2019-04-24 CN CN201980042740.2A patent/CN112566636A/zh active Pending
- 2019-04-24 MA MA052365A patent/MA52365A/fr unknown
- 2019-04-24 EP EP19792116.6A patent/EP3784234A1/fr not_active Withdrawn
- 2019-04-24 US US16/393,183 patent/US10919885B2/en active Active
- 2019-04-24 JP JP2020559520A patent/JP2021522253A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN112566636A (zh) | 2021-03-26 |
| JP2021522253A (ja) | 2021-08-30 |
| EP3784234A1 (fr) | 2021-03-03 |
| US10919885B2 (en) | 2021-02-16 |
| US20190330198A1 (en) | 2019-10-31 |
| WO2019209962A1 (fr) | 2019-10-31 |
| WO2019209962A8 (fr) | 2020-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3917529A4 (fr) | Composés et leurs utilisations | |
| EP3917527A4 (fr) | Composés et leurs utilisations | |
| MA50256A (fr) | Composés de pyrazolopyrimidinone et leurs utilisations | |
| EP3694861A4 (fr) | Composés hétérocycliques et leurs utilisations | |
| EP3768269A4 (fr) | Composés et leurs utilisations | |
| MA55385A (fr) | Composés et leurs utilisations | |
| EP3849983A4 (fr) | Composés de triazolo-pyrimidine et leurs utilisations | |
| EP3787607A4 (fr) | Compositions de caroténoïdes et leurs utilisations | |
| EP3810182A4 (fr) | Néoantigènes et leurs utilisations | |
| EP3337486A4 (fr) | Composés deutérés et leurs utilisations | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| EP3649142A4 (fr) | Composés comprenant un lieur clivable et leurs utilisations | |
| EP3658170A4 (fr) | Composés abt universels et leurs utilisations | |
| MA43205A (fr) | Composés pyy sélectifs et leurs utilisations | |
| EP3790883A4 (fr) | Composés hétéroaryles et leurs utilisations | |
| EP3902530A4 (fr) | Nanovaccins polymères et leurs utilisations | |
| EP3853216A4 (fr) | Composés substitués par pyridinyle et leurs utilisations | |
| EP3880194A4 (fr) | Composés deutérés, compositions et utilisations | |
| EP4093768A4 (fr) | Constructions cal-t et leurs utilisations | |
| EP3838900A4 (fr) | Composés de 3-aryloxy-3-aryl-propylamine et utilisations associées | |
| EP3846807A4 (fr) | Composés d'imidazoquinoléine et leurs utilisations | |
| EP3914593A4 (fr) | Composés et leurs utilisations | |
| MA48956A (fr) | Composés mic-1 et utilisations associées | |
| EP3856741A4 (fr) | Composés polymorphes et leurs utilisations | |
| EP3450444A4 (fr) | Composés de type crocine et utilisations correspondantes |